Substituted biphenyl-4-carboxylic acid arylamide analogues capable of modulating receptor activity, are provided. Such ligands may be used to modulate receptor activity in vivo or in vitro, and are particularly useful in the treatment of pain and other conditions associated with receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for receptor localization studies.
Substituted biphenyl-4-carboxylic acid arylamide analogues of the formula (I) capable of modulating receptor activity, are provided. Such ligands may be used to modulate receptor activity in vivo or in vitro, and are particularly useful in the treatment of pain and other conditions associated with receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for receptor localization studies.
From arylureas to biarylamides to aminoquinazolines: Discovery of a novel, potent TRPV1 antagonist
作者:Xiaozhang Zheng、Kevin J. Hodgetts、Harry Brielmann、Alan Hutchison、Frank Burkamp、A. Brian Jones、Peter Blurton、Robert Clarkson、Jayaraman Chandrasekhar、Rajagopal Bakthavatchalam、Stéphane De Lombaert、Marci Crandall、Daniel Cortright、Charles A. Blum
DOI:10.1016/j.bmcl.2006.07.010
日期:2006.10
Bioisosteric replacement of piperazine with an aryl ring in lead VR1 antagonist 1 led to the biarylamide series. The development of B-ring SAR led to the conformationallyconstrainedanalog 70. The resulting aminoquinazoline 70 represents a novel VR1 antagonist with improved in vitro potency and oral bioavailability vs the analogous compounds from the lead series.